Taysha Gene Therapies Inc (NASDAQ: TSHA) kicked off on Friday, up 1.48% from the previous trading day, before settling in for the closing price of $2.03. Over the past 52 weeks, TSHA has traded in a range of $1.27-$4.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 129.39% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 61.69%. With a float of $158.49 million, this company’s outstanding shares have now reached $186.96 million.
In an organization with 52 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 89.73%, operating margin of -603.4%, and the pretax margin is -888.18%.
Taysha Gene Therapies Inc (TSHA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Taysha Gene Therapies Inc is 22.67%, while institutional ownership is 72.82%. The most recent insider transaction that took place on Jun 27 ’24, was worth 2,999,999. In this transaction 10% Owner of this company bought 1,333,333 shares at a rate of $2.25, taking the stock ownership to the 1,333,333 shares. Before that another transaction happened on Nov 17 ’23, when Company’s 10% Owner bought 100,000 for $1.63, making the entire transaction worth $163,000. This insider now owns 16,566,667 shares in total.
Taysha Gene Therapies Inc (TSHA) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.93 earnings per share (EPS), lower than consensus estimate (set at -0.17) by -0.76. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 61.69% per share during the next fiscal year.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Take a look at Taysha Gene Therapies Inc’s (TSHA) current performance indicators. Last quarter, stock had a quick ratio of 5.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 32.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.87, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.13 million. That was inferior than the volume of 2.29 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 81.09%. Additionally, its Average True Range was 0.09.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 9.24%, which indicates a significant decrease from 75.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 25.39% in the past 14 days, which was lower than the 85.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.12, while its 200-day Moving Average is $2.38. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $2.07. Second resistance stands at $2.09. The third major resistance level sits at $2.11. If the price goes on to break the first support level at $2.03, it is likely to go to the next support level at $2.01. Assuming the price breaks the second support level, the third support level stands at $1.99.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
The company with the Market Capitalisation of 422.18 million has total of 187,018K Shares Outstanding. Its annual sales at the moment are 15,450 K in contrast with the sum of -111,570 K annual income. Company’s last quarter sales were recorded 1,110 K and last quarter income was -20,930 K.
